Cardiovascular Revascularization Medicine最新文献

{"title":"Diagnostic and clinical management of non-obstructive myocardial ischemia in patients with long Covid-19 syndrome and new-onset chest pain: Design and rationale of the long Covid-19 INOCA trial.","authors":"Choutchung Tinakorn Na Ayudhya, Adrián Jerónimo, Akram Lahrifa, Giulia Nardi, Hyun-Jong Lee, Alejandro Travieso, Pilar Jiménez-Quevedo, Fernando Macaya-Ten, Luis Nombela-Franco, Gabriela Tirado-Conte, Pablo Salinas, Antonio I Fernández-Ortiz, Vicente Estrada, Nieves Gonzalo, Hernán Mejía-Rentería, Javier Escaned","doi":"10.1016/j.carrev.2026.07.013","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.07.013","url":null,"abstract":"<p><strong>Background: </strong>Beyond the respiratory symptoms of acute Infection from the SARS-CoV-2 virus, there is evidence that infection with the SARS-CoV-2 virus can cause many significant long-term effects, which are currently termed \"Long Covid-19 syndrome (LCS)\". Chest pain is one of the dominant symptoms of LCS. The exact mechanism of chest pain in LCS is not fully understood but can be potentially related to endothelial and myocardial cell injury caused by SARS-CoV-2 infection.</p><p><strong>Methods: </strong>The Long Covid-19 INOCA trial is an investigator-initiated, prospective, randomized, patient- and assessor-blinded, single-center study aimed at investigating the benefits of tailored medical therapy guided by the results of coronary functional testing (CFT) compared to the routine standard of care in patients with LCS and new-onset chest pain. Additionally, the prevalence and endotypes of Ischemia with non-obstructive coronary arteries (INOCA) will also be investigated.</p><p><strong>Summary: </strong>Patients with LCS and new-onset chest pain without significant epicardial coronary artery disease will be investigated for INOCA by CFT, corresponding to the current recommendations. Patients will be randomized into 2 groups: 1) a tailored treatment group guided by the results of CFT (intervention) or 2) a routine standard of care group (control). All patients will be blinded to the CFT results. Only physicians responsible for the intervention group will receive the CFT results. Patients will undergo assessments of angina symptoms and quality of life (QoL) at baseline, 3, and 12 months. The primary objective is to evaluate improvements in angina symptoms and QoL, as assessed by the Seattle Angina Questionnaire (SAQ), with the tailored treatment compared with the standard of care. The secondary objective is to investigate the prevalence and endotypes of INOCA in LCS patients with new-onset chest pain.</p><p><strong>Conclusion: </strong>The Long Covid-19 INOCA trial will inform the value of tailored, guided treatment by CFT to improve angina symptoms in patients with LCS and new-onset chest pain. The study will also provide insights into the underlying causes of chest pain in this patient population, potentially enhancing our understanding of the pathophysiology of LCS.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148649536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preprocedural clinical and angiographic predictors of improved cardiovascular outcomes with final two-stent implantation in coronary bifurcation lesions; the Bifurcation Two-Stent (BTS) score.","authors":"Youngwoo Jang, Francesco Bruno, Jeehoon Kang, Leonardo De Luca, Minsu Kim, Ovidio de Filippo, Kyounghoon Lee, Alessio Mattesini, Woong Chol Kang, Alessandra Truffa, Hyo-Soo Kim, Wojciech Wanha, Hyeon-Cheol Gwon, Sebastiano Gili, Woo Jung Chun, Gérard Helft, Chang-Wook Nam, Bernardo Cortese, Young Bin Song, Javier Escaned, Ki Hong Choi, Alaide Chieffo, Joon-Hyung Doh, Guglielmo Gallone, Soon Jun Hong, Giorgio Quadri, Bon-Kwon Koo, Gaetano De Ferrari, Seung Hwan Han, Fabrizio D'Ascenzo","doi":"10.1016/j.carrev.2026.07.012","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.07.012","url":null,"abstract":"<p><strong>Background: </strong>Provisional stenting has become the default treatment strategy for most coronary bifurcation lesions However, in some clinical and anatomical settings, final two-stent implantation may yield better cardiovascular outcomes. This study aimed to identify preprocedural clinical and angiographic predictors associated with greater benefit from final two-stent implantation in coronary artery bifurcation lesions and to guide patient selection for this strategy.</p><p><strong>Methods: </strong>We analyzed 5333 patients with coronary bifurcation lesions (mean age 66.2 years; 76% male) from the BIFURCAT registry, an international merged dataset combining the COBIS III and RAIN registries. All patients received second-generation drug-eluting stents; 82% underwent final single-stent and 18% final two-stent implantation. The primary endpoint was major adverse cardiac events (MACE)-a composite of all-cause death, myocardial infarction, and target lesion revascularization-at 2 years. Multivariable Cox regression with interaction testing was used to identify preprocedural clinical and angiographic predictors of differential benefit from two-stent implantation.</p><p><strong>Results: </strong>Six predictors demonstrated a statistically significant interaction with final one stent and two stent implantation groups: diabetes mellitus, main vessel reference diameter > 3.0 mm, main vessel lesion length < 20 mm, side branch lesion length ≥ 20 mm, non-left main lesion, and severe coronary artery calcification. Each variable was assigned one point to construct the Bifurcation Two-Stent (BTS) score. In patients with a BTS score < 4 (80% of the cohort), final two-stent implantation was associated with significantly higher MACE rates compared with single-stent implantation (HR: 2.04; 95% CI: 1.64-2.56; P < 0.001). Conversely, patients with a BTS score ≥ 4 (approximately 20% of the cohort) demonstrated significantly lower MACE with two-stent implantation (HR: 0.56; 95% CI: 0.35-0.89; P = 0.014), driven primarily by a reduction in hard endpoints including death and myocardial infarction. These findings remained consistent after adjustment for procedural variables and antiplatelet therapy.</p><p><strong>Conclusion: </strong>The BTS score may help identify patients with coronary bifurcation lesions who are most likely to benefit from final two-stent implantation. In patients with BTS score ≥ 4, final two-stent implantation was associated with lower MACE and hard clinical endpoints, supporting a selective rather than routine two-stent strategy in bifurcation PCI.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148649513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous embolectomy vs medical therapy for acute pulmonary embolism in patients with cancer.","authors":"Song Peng Ang, Jaikrishnan Ram, Michel T Corban, Madhan Shanmugasundaram","doi":"10.1016/j.carrev.2026.07.009","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.07.009","url":null,"abstract":"<p><strong>Background: </strong>Cancer-associated acute pulmonary embolism (PE) carries high morbidity and mortality, compounded by elevated bleeding risks. While percutaneous therapies are increasingly utilized, robust comparative effectiveness data in this high-risk oncologic population remain scarce.</p><p><strong>Aim: </strong>To evaluate temporal trends, safety, and clinical outcomes of percutaneous embolectomy versus medical therapy in cancer patients presenting with acute PE.</p><p><strong>Methods: </strong>We analyzed the National Inpatient Sample (2016-2021) for adult cancer patients hospitalized with acute PE. Patients were stratified by receipt of percutaneous embolectomy or medical therapy alone. The primary outcome was in-hospital mortality. Propensity-score matching (PSM) (1:3) was utilized to adjust for baseline demographics and hospital characteristics.</p><p><strong>Results: </strong>Among 476,915 weighted hospitalizations, 2760 (0.6%) underwent percutaneous embolectomy. Utilization increased significantly from 0.16% in 2016 to 1.35% in 2021. The embolectomy cohort exhibited substantially higher baseline clinical acuity, including elevated rates of PE-related shock (46.6% vs 5.2%; P < 0.001). After PSM (n = 11,040), in-hospital mortality did not differ significantly between the percutaneous and medical therapy groups (OR: 0.87; 95% CI: 0.63-1.21). The embolectomy cohort demonstrated similar rates of major bleeding (OR: 0.95; 95% CI: 0.61-1.48) but higher rates of acute kidney injury (OR: 1.36; 95% CI: 1.09-1.71).</p><p><strong>Conclusions: </strong>In cancer patients with acute PE, percutaneous embolectomy utilization is rapidly increasing. Despite being performed in a cohort with profound hemodynamic instability, embolectomy was associated with comparable survival and major bleeding rates to medical management.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of route and location of contrast delivery on contrast-induced nephropathy: A systematic review and pairwise meta-analysis.","authors":"Muhammad Sabih Saleem, Dipen Zalavadia, Tejas M Patel, Samir B Pancholy","doi":"10.1016/j.carrev.2026.07.011","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.07.011","url":null,"abstract":"<p><strong>Background: </strong>Contrast-induced nephropathy (CIN) remains a leading cause of iatrogenic acute kidney injury. Whether the route of contrast administration (intravenous [IV] versus intra-arterial [IA]) and the anatomical level of endovascular manipulation (suprarenal versus infrarenal) independently modify CIN risk is incompletely defined. We hypothesized that direct first-pass exposure of the renal vasculature to contrast and procedure-related embolic stress drive renal injury.</p><p><strong>Methods: </strong>We performed two pairwise random-effects meta-analyses. The first compared CIN incidence after IV versus IA contrast administration across six eligible studies (n = 2961 patients). The second compared CIN incidence after suprarenal versus infrarenal endovascular procedures across fifteen studies (n = 49,838 patients). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) and 95% prediction intervals were calculated using the DerSimonian-Laird estimator.</p><p><strong>Results: </strong>IV contrast administration was associated with a significantly lower incidence of CIN compared with IA administration (pooled OR 0.63, 95% CI 0.40-0.97; p = 0.036; I² = 48%). Suprarenal endovascular procedures were associated with a significantly higher incidence of CIN than infrarenal procedures (pooled OR 1.27, 95% CI 1.01-1.60; p = 0.043; I² = 43%). Meta-regression showed that differences in weighted mean contrast volume and incidence of diabetes mellitus significantly explained between study heterogeneity.</p><p><strong>Conclusions: </strong>These findings support the hypothesis that route of contrast delivery and anatomical proximity of endovascular instrumentation to the renal arteries are independent determinants of CIN, supporting the first-pass high concentration exposure and embolic stress as plausible etiologies of renal injury associated with contrast requiring procedures.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148608322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment effect of lipid-lowering strategy measured by intracoronary near-infrared spectroscopy (NIRS)-derived lipid core burden index (LCBI): A systematic review and meta-analysis.","authors":"Aninka Saboe, Pablo Rubio, Jorge Sanz-Sánchez, José Antonio Sorolla Romero, Ron Waksman, Hector M Garcia-Garcia","doi":"10.1016/j.carrev.2026.07.010","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.07.010","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the effect of lipid-lowering therapies on the change of near-infrared spectroscopy (NIRS)-derived maximum lipid core burden index within a 4-mm segment (maxLCBI4mm).</p><p><strong>Methods: </strong>A systematic review and meta-analysis of studies comparing lipid-lowering therapies reporting baseline and follow-up NIRS-derived maxLCBI4mm in patients with coronary artery disease (CAD) was performed. Data were pooled by meta-analysis using a random-effects model. The prespecified primary endpoint was the reduction of maxLCBI4mm at follow-up. Subgroup analyses were performed according to follow-up duration and proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) use.</p><p><strong>Results: </strong>Seven studies, comprising a total of 920 lesions, were included. Overall, lipid-lowering therapy was not associated with a statistically significant reduction in maxLCBI4mm (SMD -0.18; 95% CI -0.42 to 0.07; p = 0.15, I² = 60.5%). Subgroup analyses revealed no significant differences in terms of follow-up duration or PCSK9i use.</p><p><strong>Conclusions: </strong>Lipid-lowering therapies were not associated with a statistically significant overall reduction in NIRS-derived maxLCBI4mm in this study-level meta-analysis. Although the direction of effect numerically favored more intensive lipid-lowering strategies, including PCSK9 inhibitor-based regimens, these findings remained non-significant and should be interpreted cautiously. Larger, methodologically rigorous studies are needed to determine whether specific therapies or patient subgroups derive measurable plaque lipid reduction on serial NIRS imaging and whether such imaging changes translate into improved clinical outcomes.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early pericardial complications after left atrial appendage occlusion and long-term clinical outcomes: A propensity-matched analysis.","authors":"Adham Ramadan, Mohamed Doma, Jibran Ikram, Muhammad Ehsan, Benjamin Horn, Allan L Klein, Andrew M Goldsweig","doi":"10.1016/j.carrev.2026.07.008","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.07.008","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year clinical outcomes after drug-coated balloon-only angioplasty for de novo lesions in non-small coronary vessels.","authors":"Aninka Saboe, Yusuf Januar Rasyid, Dendi P Wahyudi, A Fauzi Yahya, Hector M Garcia Garcia","doi":"10.1016/j.carrev.2026.07.007","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.07.007","url":null,"abstract":"<p><strong>Background: </strong>Evidence for drug-coated balloon (DCB)-only angioplasty in de novo non-small coronary vessels remains limited. We evaluated procedural feasibility, 12-month clinical outcomes, and exploratory correlates of major adverse cardiac events (MACE).</p><p><strong>Methods: </strong>This single-center retrospective registry included 207 patients who underwent successful DCB-only angioplasty for a de novo lesion in a non-small coronary vessel, defined as reference vessel diameter ≥ 3.0 mm, and completed 12-month follow-up. Procedural feasibility was assessed in all 218 patients in whom a DCB-only strategy was attempted. The primary endpoint was first MACE, defined as all-cause death, myocardial infarction, or clinically driven target lesion revascularization (CD-TLR). Event timing was summarized using the Kaplan-Meier method, and adjusted associations were evaluated using Firth penalized logistic regression because of the limited number of events.</p><p><strong>Results: </strong>Among 218 patients in whom DCB-only angioplasty was attempted, 3 required bailout stenting (1.4%). Of the remaining 215 patients successfully treated with DCB alone, 8 were lost to follow-up before 12 months, leaving 207 patients for the clinical outcome analysis. Reference vessel diameter was assessed by angiography and, when available, IVUS or OCT, and DCB diameter was selected accordingly. A 3.0-mm DCB was used in 130 patients (62.8%), a 3.5-mm DCB in 65 (31.4%), and a 4.0-mm DCB in 12 (5.8%); overall, 77 patients (37.2%) had a reference vessel diameter ≥ 3.5 mm. At 12 months, MACE occurred in 13 patients (6.3%), including CD-TLR in 10 (4.8%) and myocardial infarction in 3 (1.5%); no deaths occurred. Kaplan-Meier freedom from MACE at 12 months was 93.7% (95% CI, 89.4%-96.3%). In exploratory Firth analysis, intravascular imaging was associated with lower odds of MACE (adjusted OR, 0.12; 95% profile penalized-likelihood CI, 0.03-0.43; p = 0.001), whereas acute coronary syndrome (ACS) was associated with higher odds (adjusted OR, 8.01; 95% profile penalized-likelihood CI, 2.33-35.52; p < 0.001).</p><p><strong>Conclusions: </strong>Among patients who underwent successful DCB-only angioplasty and completed 12-month follow-up, MACE occurred in 6.3%. The bailout-stenting rate was 1.4% among all attempted DCB-only procedures. These findings suggest that DCB-only angioplasty may be feasible in carefully selected non-small coronary vessels but do not establish equivalence to drug-eluting stents. The associations with intravascular imaging and ACS should be considered exploratory.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148457151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-time CPR feedback in out-of-hospital cardiac arrest: A systematic review of CPR quality and outcomes.","authors":"Antonella Mariapia Capone, Anna Grimaldi, Mauro Parozzi, Daniele Napolitano, Diego Lopane, Anna Iavarone, Federica Colella, Gianluca Marino, Stefano Mancin","doi":"10.1016/j.carrev.2026.06.013","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.06.013","url":null,"abstract":"<p><strong>Background: </strong>Out-of-hospital cardiac arrest (OHCA) remains a major cause of mortality in industrialised countries, with survival highly dependent on high-quality cardiopulmonary resuscitation (CPR). Real-time feedback systems have been introduced to optimise CPR performance by improving compression depth, rate, chest compression fraction (CCF), and recoil.</p><p><strong>Aim: </strong>To evaluate the effectiveness of real-time feedback systems on CPR quality indicators and clinical outcomes in adult OHCA patients treated by prehospital emergency medical services.</p><p><strong>Methods: </strong>A systematic review was conducted according to PRISMA 2020 guidelines and registered in PROSPERO (CRD420261290413). Searches were performed in MEDLINE/PubMed, Embase, CINAHL, and Scopus, supplemented by ClinicalTrials.gov and grey literature. Eligible studies included primary research conducted in real prehospital settings with comparator groups. Risk of bias was assessed using RoB 2 and ROBINS-I, while certainty of evidence was evaluated with GRADE. Narrative synthesis with vote-counting was performed.</p><p><strong>Results: </strong>Six studies involving 16,683 OHCA patients from five countries (2011-2022) were included. Interventions comprised audiovisual feedback integrated into monitor-defibrillators, AED-based feedback for bystanders, structured CPR improvement bundles, and video-assisted dispatcher CPR. One cluster-RCT showed improvements in CPR quality indicators, including CCF (64% vs 66%), compression depth (38 vs 40 mm), and incomplete recoil (15% vs 10%). However, no significant improvements were observed in ROSC, survival to hospital discharge, or favourable neurological outcomes. Evidence certainty ranged from moderate for CPR quality outcomes to very low for clinical outcomes.</p><p><strong>Conclusions: </strong>Real-time feedback systems may improve technical CPR quality in prehospital care, but current evidence does not demonstrate consistent clinical benefits.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Wireless percutaneous coronary intervention guidance - From angiography to physiology.","authors":"Edward Koifman, Tomer Stahi","doi":"10.1016/j.carrev.2026.07.005","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.07.005","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148608425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter to the editor.","authors":"Ziad Arow","doi":"10.1016/j.carrev.2026.07.004","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.07.004","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148425153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}